key: cord-0825731-7k4yfsfm
authors: Kojima, N.; Klausner, J. D.
title: Usage and awareness of antiviral medications for COVID-19
date: 2022-04-22
journal: nan
DOI: 10.1101/2022.04.21.22274155
sha: ee9d3af9edf3d21602cfbb4b2333ab9454f356c4
doc_id: 825731
cord_uid: 7k4yfsfm

We surveyed people that recently tested positive for SARS-CoV-2 to assess the frequency and correlates of early treatment seeking behavior. Among high risk respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection. More public outreach is needed to raise awareness of the benefits of treatment for COVID-19.

90095. Email: nkojima@ucla.edu 23 24 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

We surveyed people that recently tested positive for SARS-CoV-2 to assess the 26 frequency and correlates of early treatment seeking behavior. Among high risk 27 respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought 28 treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection. 29

More public outreach is needed to raise awareness of the benefits of treatment for 30 COVID-19. 31 32 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 4 Due to the timing of the survey, infections were most likely caused by either the 56

Omicron variant of SARS-CoV-2 or a sublineage of the Omicron variant, which might be 57 less severe in those with prior immunity [5] . Our findings demonstrate that increased 58 awareness and use of antivirals among those at risk for severe disease due to COVID-59 19 are urgently needed among individuals that test positive for SARS-CoV-2. To the participants that donated their time. 72 73 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 1 Figure. Treatment awareness, treatment seeking behavior, and use of antiviral medications among individuals 65 years 92 and older versus individuals younger than 65 years that tested positive for SARS-CoV-2 infection in 37 States in the 93 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. 

Antibody Combination to Prevent Covid-19

Early Treatment for Covid-19 with 78 SARS-CoV-2 Neutralizing Antibody Sotrovimab

Molnupiravir -A Step toward Orally Bioavailable Therapies for Covid-81 19

Effect of early treatment 83 with fluvoxamine on risk of emergency care and hospitalisation among patients 84 with COVID-19: the TOGETHER randomised, platform clinical trial

Covid-19: Early studies give hope omicron is milder than other 87 variants

Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of 89 serious illness, company reports